Abstract: The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D3, coated with zwitterionic chitosan (ZWC) and polymyxin B (PMB). The invention described herein also pertains to pharmaceutical compositions and methods for the treatment of sepsis.

Abstract: The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D3, coated with zwitterionic chitosan (ZWC) and polymyxin B (PMB). The invention described herein also pertains to pharmaceutical compositions and methods for the treatment of sepsis.

Abstract: A formulation to deter abuse of a drug by smoking comprising a physical barrier having properties to entrap the drug and thermal degradation products thereof. The physical barrier is in the form of an additive or a polymer network or a combination thereof.

Abstract: The present disclosure generally relates to a composition matter and a method for cancer treatment. In particular, a composition of soft, non-cationic nanocapsules, termed Nanosac, for systemic delivery of siRNA. Nanosac is produced by sequential attachment of siRNA and polydopamine on a sacrificial MSN core, followed by removal of the MSN. Encapsulating siRNA in the capsules, Nanosac avoids the issues common to cationic gene carriers, such as toxicity and non-specific protein binding while protecting siRNA from RNase. Nanosac entered tumor cells by caveolae-mediated endocytosis, likely via albumin recruited from serum, trafficked to the cytosol, and silenced target genes.

Abstract: In an embodiment an apparatus for controlling a speed of a vehicle includes a communication device configured to receive at least one of a starting point of a speed trap, an end point of the speed trap, a speed limit in the speed trap, an average speed of the vehicle, a traveling distance from the starting point of the speed trap of the vehicle, or a present speed of the vehicle, a target speed setting device configured to set a target point, set a starting point for a target speed, and calculate the target speed, a required acceleration calculating device configured to calculate a required acceleration, and a controller configured to control the vehicle, based on at least one of the calculated target speed or the calculated required acceleration.

Abstract: In an embodiment an apparatus includes a communication device configured to receive at least one of a starting point of a speed trap, an end point of the speed trap, a speed limit in the speed trap, an average speed of the vehicle, a traveling distance from the starting point of the speed trap of the vehicle, or a present speed of the vehicle, a target speed setting device configured to set a target point, to set a starting point for a target speed, and to calculate the target speed, a required acceleration calculating device configured to calculate a required acceleration, and a controller configured to control the vehicle based on at least one of the calculated target speed or the calculated required acceleration.

Abstract: Drug delivery devices that have a flexible film, an array of nanoscopic, porous needles attached to a surface of the flexible film, and a therapeutic drug cargo loaded onto the needles. The drug delivery device may be applied to living tissue such that the surface of the flexible film contacts the living tissue and some or all of the needles are inserted into the tissue. The flexible film may then be dissolved while leaving the needles inserted in the tissue. The needles degrade in the living tissue over time causing release of the therapeutic drug cargo loaded onto the needles.

Abstract: The present invention relates to pharmaceutical formulations for long-term ocular delivery of the active agents. The present invention further provides the long-term ocular delivery of griseofulvin with specific in vitro release profile. These formulations are used for the treatment of neovascular eye diseases and age-related macular degeneration (AMD). In particular, the present invention provides microparticles & nanoparticles of griseofulvin for the long-term ocular delivery and methods of preparation of such formulations.

Abstract: An apparatus and method for recognizing a driving lane of a vehicle are provided. The apparatus includes an information acquisition device that acquires forward information of a road on which the vehicle is driving, and a processor that recognizes an entrance section and an exit section on a front left side of the vehicle based on the forward information, and determines a driving lane of the vehicle by correcting a number of lanes of the road in the entrance section and the exit section.

Abstract: The present disclosure generally relates to a composition matter and a method for cancer treatment comprising albumin (alb) coated tannic acid-Fe nanoparticles (NPs) with a therapeutic compound, and one or more diluents, excipients or carriers. In particular, the present invention provides a treatment by enhancing antitumor immunity using tannic acid-based nanoparticles containing a therapeutic cancer treatment that can induce immunogenic cell death (ICD). The method disclosed herein provides a potential solution to the immunotoxicity accompanying the ICD cancer immunotherapy by intratumoral or intravenous administration of a nanocapsule formulation of carfilzomib (CFZ), an ICD-inducing proteasome inhibitor, using interfacial supramolecular assembly of tannic acid (TA) and iron, supplemented with albumin coating for better metabolic stability.

Abstract: The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D3, coated with zwitterionic chitosan (ZWC) and polymyxin B (PMB). The invention described herein also pertains to pharmaceutical compositions and methods for the treatment of sepsis.

Abstract: The present disclosure relates to a driver assistance apparatus and a method for operating the same. The driver assistance apparatus includes a navigation device that provides a guide route and road information, a detector that measures information regarding surroundings of a vehicle, and a processor that performs a deceleration control for entrance to an exit ramp, based on the information obtained through the navigation device and the detector.

Abstract: The present invention generally relates to a method for preparing a drug-loaded liposome, in particular to a method for preparing a drug-loaded liposome manufactured using hypertonic loading or a combination of hypertonic loading and remote loading of one or more drugs. The invention described herein also pertains to pharmaceutical compositions and methods for treating cancers. Both the manufacturing processes and the pharmaceutical products are within the scope of this disclosure.

Abstract: Drug delivery devices that have a flexible film, an array of nanoscopic, porous needles attached to a surface of the flexible film, and a therapeutic drug cargo loaded onto the needles. The drug delivery device may be applied to living tissue such that the surface of the flexible film contacts the living tissue and some or all of the needles are inserted into the tissue. The flexible film may then be dissolved while leaving the needles inserted in the tissue. The needles degrade in the living tissue over time causing release of the therapeutic drug cargo loaded onto the needles.

Abstract: An apparatus and method for recognizing a driving lane of a vehicle are provided. The apparatus includes an information acquisition device that acquires forward information of a road on which the vehicle is driving, and a processor that recognizes an entrance section and an exit section on a front left side of the vehicle based on the forward information, and determines a driving lane of the vehicle by correcting a number of lanes of the road in the entrance section and the exit section.

Abstract: A driving controlling apparatus and method of a vehicle is provided. The apparatus includes a navigation device providing a guide route and a travelable route and a controller. The controller is configured to determine one of the guide route and the travelable route as a driving control target depending on a result of determining whether to deviate from the guide route and a result of determining whether the guide route is set on a pocket-shaped off ramp and the vehicle is driving on an outermost lane of a road on which the vehicle is currently driving.

Abstract: The present invention generally relates to targeted nanoparticle delivery to E-selectin- or P-selectin-positive cells or tissues. In particular, this invention discloses a method for preparing quinic acid-modified nanoparticles for targeted drug delivery to cancerous cells or tissues via E-selectin- or P-selectin-mediated transcytosis. The invention described herein also pertains to pharmaceutical compositions and methods for treating cancers.

Abstract: The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).

Abstract: An apparatus for automatically controlling a driving assist function of a vehicle includes a sensing device to sense surrounding information and driving information of the vehicle and a state of a driver, a controller to determine whether an automatic activation condition for automatically activating the driving assist function is satisfied, based on the surrounding information and the driving information of the vehicle, which are acquired from the sensing device, and the sensed driver state, and automatically activate the driving assist function when the automatic activation condition is satisfied.

Abstract: An apparatus for automatically setting a speed of a vehicle may include a path guide device configured to obtain information related to a location of the vehicle, a type of a road corresponding to the location, and a speed limit of the road corresponding to the location and a controller configured to be electronically connected to the path guide device, wherein the controller is configured to activate an automatic setting mode for setting a setting speed for autonomous driving of the vehicle to a speed limit of a road corresponding to a current location of the vehicle, when the vehicle enters another type of road from the specified type of road in a state where the automatic setting mode is activated, release the automatic setting mode, and activate the automatic setting mode.